First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)

Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) — AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial AskBio initiated recruitment in the United States earlier in 2026, with enrollment ongoing AskBio Inc. (AskBio), a gene therapy company wholly owned and independently […]